Welcome to our dedicated page for ACLARION news (Ticker: ACONW), a resource for investors and traders seeking the latest updates and insights on ACLARION stock.
Aclarion, Inc. (Nasdaq: ACON, ACONW) generates frequent news as a commercial-stage healthcare technology company focused on chronic low back pain diagnostics. The company’s updates center on its Nociscan SaaS platform, which uses Magnetic Resonance Spectroscopy (MRS), proprietary signal processing, biomarkers, and augmented intelligence algorithms to help physicians distinguish between painful and nonpainful lumbar discs.
News about Aclarion often highlights clinical and scientific milestones. These include progress in the pivotal CLARITY randomized trial, which evaluates whether incorporating Nociscan into surgical planning can improve outcomes for patients undergoing surgery for chronic low back pain, as well as publications of real-world evidence and peer-reviewed articles describing Nociscan’s clinical and economic value. Company announcements also cover participation in major spine and neuroscience meetings and recognition in digital health award programs.
Investors and clinicians following Aclarion can expect updates on market adoption, such as growth in Nociscan scan volumes, expansion of imaging centers and physician users, and developments in reimbursement, including private insurer coverage in the United Kingdom. Corporate news includes capital raises, balance sheet developments, executive appointments, and governance events reported through both press releases and SEC filings.
This news feed aggregates these items so readers can track how Aclarion advances its Nociscan platform, builds clinical evidence, and executes its commercial strategy in the diagnostic imaging and spine care space. For those monitoring ACON and ACONW, the page provides a centralized view of company announcements, clinical trial progress, and strategic updates over time.
Aclarion (NASDAQ: ACON) received a Diamond Pinnacle Award for AI Innovation in Clinical Decision AI on April 14, 2026, recognizing its Nociscan MR spectroscopy–based SaaS platform for identifying biochemical markers of discogenic chronic low back pain.
The company cites a 97% surgical success rate when all Nociscan-positive discs are treated and notes global prevalence estimates of 266 million people with degenerative spine disease and low back pain.
Aclarion (Nasdaq: ACON) announced a commercial agreement with Weill Cornell Medicine to bring Nociscan to Weill Cornell and Och Spine at NewYork-Presbyterian/Weill Cornell Medical Center. A subset of spine patients in an IRB-approved trial (Protocol No. 22-06024915) will be eligible for Nociscan to help identify discogenic low back pain.
The study investigates dose and quantity of concentrated bone marrow aspirate (BMAC) for osteoarthritis and degenerative disc disease, with Nociscan used alongside other diagnostics.
Aclarion (Nasdaq: ACON) released a new physician video (April 7, 2026) featuring Mr. John Sutcliffe of The London Spine Clinic demonstrating real-world use of Nociscan to evaluate chronic low back pain.
Nearly 100 Nociscans have been performed at The London Clinic; Nociscan uses MR spectroscopy and proprietary signal processing to identify chemical biomarkers linked to disc pain. According to the company, clinical data showed up to 97% surgical success when all Nociscan-positive discs are treated, and the video signals growing physician adoption at a leading international center.
Aclarion (Nasdaq: ACON, ACONW) announced that its Board adopted a limited duration stockholder rights plan effective March 19, 2026 that expires in one year. The Rights Plan is intended to help stockholders realize long-term value and to reduce the likelihood of control changes without an appropriate premium.
The plan applies equally to all current and future stockholders, was adopted unanimously by the Board, and was not adopted in response to any specific acquisition proposal.
Aclarion (Nasdaq: ACON, ACONW) published a CEO shareholder letter outlining 2026 priorities: expand adoption of the Nociscan platform, pursue reimbursement with U.S. regional insurers, grow clinical evidence, and advance commercial engagement with physicians and imaging centers.
The company highlighted an initial CLARITY trial readout in Q4 2026 and a strong balance sheet with cash runway into 2028 to support execution of these catalysts.
Aclarion (Nasdaq: ACON, ACONW) will participate in the 38th Annual ROTH Conference March 22-24, 2026, in Dana Point, CA to meet institutional investors and analysts.
CEO Brent Ness will hold one-on-one meetings to discuss progress advancing Nociscan, the company’s MR spectroscopy platform, and emphasize a strong balance sheet, no debt, and plans to expand adoption in the UK and US.
Aclarion (Nasdaq: ACON) announced that CEO Brent Ness will attend LSI USA 2026 in Dana Point, CA, March 16-20, 2026, to meet investors and potential partners.
Mr. Ness will discuss progress advancing NOCISCAN, Aclarion’s MR spectroscopy platform using biomarkers and AI to help identify painful vs non-painful spinal discs. Investors may request 1-on-1 meetings via the provided contact emails.
Aclarion (Nasdaq: ACON) published its 2026 shareholder letter outlining clinical, financial, and operational priorities. The company expects an initial internal readout of its 300-patient CLARITY trial at the end of Q3 2026 and plans a public disclosure of early interim results in Q4 2026.
Key facts: cash runway into 2028, ATM terminated in early 2025, ELOC expired December 31, 2025, and 2,882,371 fully diluted shares outstanding. The company emphasizes a cloud-delivered, software-native MedTech model and will pursue an investor-awareness program focused on institutional healthcare investors and physician education.
Aclarion (Nasdaq: ACON) expanded Nociscan availability by establishing an agreement with Source Healthcare in Los Angeles on Feb 3, 2026 to integrate Nociscan into the clinic’s spine and pain pathways.
The partnership will generate real-world evidence comparing Nociscan to anesthetic discography and aims to strengthen clinical validation and payer/provider adoption for the non-invasive MR spectroscopy test.
Aclarion (Nasdaq: ACON, ACONW) closed a $10.4 million common-stock-only financing at $5.18 per share, leaving the company with $21.6 million in cash as of Jan 12, 2026 and a debt-free balance sheet. Management says the transaction materially strengthens the balance sheet, preserves capital-structure integrity and extends the company's operating runway into 2028 under current plans. The company plans to accelerate CLARITY trial enrollment (targeting ~25% of patients by end of Q2 2026), publish multiple investigator-initiated real-world studies, expand MRI manufacturer access (>30% larger available market), launch Nociscan software v2.8 in Q1, and pursue broader US payer engagement.